CTI BioPharma Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Net Income	-3,750	-7,950	-2,719	-3,860	1,509	-24,450	Upgrade
Depreciation & Amortization	1,013	1,013	748.93	278	118.11	732.61	Upgrade
Other Operating Activities	3,335	-2,012	3,039	2,182	-787.73	14,280	Upgrade
Operating Cash Flow	598.23	-8,949	1,068	-1,400	839.1	-9,438	Upgrade
Capital Expenditures	-2,124	-2,110	-324.41	-209.88	-209.46	-133.44	Upgrade
Sale of Property, Plant & Equipment	171.89	175.41	87.39	-	-	184.44	Upgrade
Other Investing Activities	721.87	-373.8	-	-	-	-	Upgrade
Investing Cash Flow	-1,230	-2,308	-237.02	-209.88	-209.46	51	Upgrade
Long-Term Debt Repaid	-	-899.13	-	-631.04	-	-	Upgrade
Total Debt Repaid	-1,017	-899.13	-	-631.04	-	-	Upgrade
Net Debt Issued (Repaid)	-1,017	-899.13	-	-631.04	-	-	Upgrade
Financing Cash Flow	-1,017	-899.13	-	-631.04	-	-	Upgrade
Foreign Exchange Rate Adjustments	-10.72	-1.13	6.96	173.79	7.16	35.95	Upgrade
Net Cash Flow	-1,660	-12,158	838.16	-2,067	636.8	-9,351	Upgrade
Free Cash Flow	-1,526	-11,059	743.81	-1,609	629.64	-9,571	Upgrade
Free Cash Flow Margin	-3.20%	-28.01%	1.75%	-3.44%	1.34%	-22.59%	Upgrade
Free Cash Flow Per Share	-3.28	-23.77	1.60	-3.46	1.35	-20.57	Upgrade
Cash Interest Paid	122.34	122.34	33.07	87.55	17.67	27.29	Upgrade
Cash Income Tax Paid	654.07	654.07	909.78	-1,048	-1,044	323.2	Upgrade
Levered Free Cash Flow	861.37	-7,724	2,603	-2,286	-753.81	-4,240	Upgrade
Unlevered Free Cash Flow	992.03	-7,648	2,635	-2,231	-742.77	-4,223	Upgrade
Change in Net Working Capital	-4,221	1,558	-3,867	-1,499	115.39	-7,992	Upgrade

Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.